Patents Represented by Attorney, Agent or Law Firm Bernard F. Rose
-
Patent number: 6825009Abstract: The present invention relates to methods for the detection of polymorphism in polynucleotides by using hybridization of fragments of segments of a polynucleotide suspected of containing a polymorphism with an oligonucleotide having a sequence complementary to a fragment identifying the polymorphism and subsequent detection of incorporated labels in the oligonucleotide-fragment duplex.Type: GrantFiled: March 22, 2002Date of Patent: November 30, 2004Assignee: Variagenics, Inc.Inventors: Vince P. Stanton, Jr., Jia Liu Wolfe, Tomohiko Kawate, Gregory L. Verdine, Jeffrey Olson, Colin W Dykes
-
Patent number: 6777188Abstract: The present invention relates to a method for genotyping a diploid organism by cleaving segments of two alleles such that 7-20 nucleotide fragments that contain a suspected polymorphic locus are produced and comparing the masses of those fragments.Type: GrantFiled: March 26, 2002Date of Patent: August 17, 2004Assignee: Variagenics, Inc.Inventors: Vincent P. Stanton, Jr., Jeffrey Olson, Jia Liu Wolfe, Martin Zillmann
-
Patent number: 6750038Abstract: This invention relates to a method for the rapidly determining the susceptibility of bacteria to antibiotics using histochemical detection of enzyme inhibition by the antibiotic.Type: GrantFiled: August 1, 2001Date of Patent: June 15, 2004Assignee: Essential Therapeutics, Inc.Inventor: Paul K. Nakane
-
Patent number: 6723716Abstract: The present invention relates to a cephem prodrug having formula III or formula IV: or a pharmaceutically acceptable salt thereof, wherein R′1 is selected from the group consisting of hydrogen and —C(O)CH(NH2)CH3 and R′2 is selected from the group consisting of hydrogen and an acyl group that is cleaved by an enzyme found in mammals, with the proviso that, when either R′1 or R′2 is hydrogen, the other is not. A, B, L, G, E, and J are each independently nitrogen or carbon such that the respective rings are selected from the group consisting of provided that the group —CH2—S—CH2CH2NHR′2 is attached only to a carbon atom of said heterocyclic group, and Q is selected from the group consisting of nitrogen and —CX, wherein X is selected from the group consisting of hydrogen and chlorine.Type: GrantFiled: September 21, 2000Date of Patent: April 20, 2004Assignee: Essential Therapeutics, Inc.Inventors: Scott J. Hecker, Aesop Cho, Tomasz W. Glinka, Trevor Calkins, Ving J. Lee
-
Patent number: 6692734Abstract: The present invention relates to purified platinum complexes in which platinum is coordinated to form a single N,O- or O,O-chelate of an amidomalonate. The chelates, and pharmaceutically acceptable formulations thereof, are useful for the treatment of cancer. The platinum chelates may additionally be linked to one or more functional groups which increases water solubility and/or assists in tumor targeting of the chelate. Examples of tumor targeting moieties include polymers, in which one or more platinum chelates are attached to the polymer backbone via linkers capable of being cleaved in the body, and molecules with a high affinity for receptors which are concentrated or upregulated in tumor tissue and/or the tumor vasculature.Type: GrantFiled: January 4, 2001Date of Patent: February 17, 2004Assignee: Access Pharmaceuticals, Inc.Inventors: Donald R. Stewart, John R. Rice, John V. St. John
-
Patent number: 6689782Abstract: This invention relates to compounds that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism.Type: GrantFiled: December 30, 2002Date of Patent: February 10, 2004Assignee: Essential Therapeutics, Inc.Inventors: William J. Watkins, Remy Lemoine, Aesop Cho, Monica Palme
-
Patent number: 6638718Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 17, 2000Date of Patent: October 28, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6630303Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial pathogenesis genes or essential genes, which are expressed in vivo. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: March 17, 2000Date of Patent: October 7, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Ving J. Lee, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6610492Abstract: The present invention is directed to novel base-modified nucleotides and methods for their use in the preparation and cleavage of modified polynucleotides.Type: GrantFiled: January 8, 2002Date of Patent: August 26, 2003Assignee: Variagenics, Inc.Inventors: Vincent P. Stanton, Jr., Jia Liu Wolfe, Tomohiko Kawate, Charles Allerson, Gregory L. Verdine
-
Patent number: 6599893Abstract: The present invention relates to chemical compounds having the formula: or a pharmaceutically acceptable salt thereof. R1 is selected from the group consisting of: R2 is selected from the group consisting of hydrogen, CH3—, FCH2—, F2CH— R3 is selected from the group consisting of: X is selected from the group consisting of hydrogen, halogen, cyano, —NH2, —N(CH3)2, —HSO2NH2, —SO2NH2 and —SCH3. The subscript n is 0 or 1.Type: GrantFiled: August 8, 2001Date of Patent: July 29, 2003Assignee: Essential Therapeutics, Inc.Inventor: Tomasz W. Glinka
-
Patent number: 6596723Abstract: This invention relates to compounds that are efflux pump inhibitors and therefore are useful as potentiators of anti-fungal agents for the treatment of infections caused by fungi that employ an efflux pump resistance mechanism.Type: GrantFiled: July 16, 2001Date of Patent: July 22, 2003Assignee: Essential Therapeutics, Inc.Inventors: Will J. Watkins, Remy Lemoine, Aesop Cho, Thomas E. Renau
-
Patent number: 6582923Abstract: The present invention relates to a method of synthesizing a polynucleotide with incorporation of a modified nucleotide.Type: GrantFiled: March 22, 2002Date of Patent: June 24, 2003Assignee: Variagenics, Inc.Inventors: Vincent P. Stanton, Jr., Jia Liu Wolfe, Tomohiko Kawate, Gregory L. Verdine
-
Patent number: 6569580Abstract: The present invention relates to photomasks for use in semiconductor chip manufacture.Type: GrantFiled: March 13, 2001Date of Patent: May 27, 2003Assignee: Diverging Technologies, Inc.Inventors: Jim G. Campi, Douglas J. Van Den Broeke
-
Patent number: 6566059Abstract: The present invention relates to methods for the analysis of polynucleotides including detection of variance in nucleotide sequence without the need for full sequence determination, full sequence determination of a polynucleotide, genotyping of DNA and labeling a polynucleotide fragment during the process of cleaving it into fragments.Type: GrantFiled: September 10, 1999Date of Patent: May 20, 2003Assignee: Variagenics, Inc.Inventors: Vincent P. Stanton, Jr., Jia Liu Wolfe, Gregory L. Verdine
-
Patent number: 6551591Abstract: The present invention provides a novel strain of Microbispora corallina, means for identifying it, methods for culturing it at several different levels, two new antibiotics derived from the cultures and the physico-chemical characteristics of those compounds and their biological activity against a variety of microorganisms.Type: GrantFiled: September 7, 2001Date of Patent: April 22, 2003Assignee: Essential Therapeutics, Inc.Inventor: May D. Lee
-
Patent number: 6514746Abstract: This disclosure describes isolated or purified deoxyribonucleotide (DNA) sequences, useful for the development of antibacterial agents, which contain the coding sequences of bacterial genes which encode the components of a two-component regulatory pair. It further describes isolated or purified DNA sequences which are portions of such bacterial genes, which are useful as probes to identify the presence of the corresponding gene or the presence of a bacteria containing that gene. Also described are hypersensitive mutant cells containing a mutant gene corresponding to any of the identified sequences and methods of screening for antibacterial agents using such hypersensitive cells. In addition it describes methods of treating bacterial infections by administering an antibacterial agent active against one of the identified targets, as well as pharmaceutical compositions effective in such treatments.Type: GrantFiled: May 20, 1998Date of Patent: February 4, 2003Assignee: Essential Therapeutics, Inc.Inventors: Bret Benton, Francois Malouin, Patrick K. Martin, Molly B. Schmid, Dongxu Sun
-
Patent number: 6495591Abstract: The use of compounds of the milbemycin class as inhibitors of efflux pumps in microbes or other cells is described, along with pharmaceutical compositions incorporating a milbemycin. Also described is a method of screening for compounds which inhibit a CDR1, CDR2, BEN, or FLU1 efflux pump or a pump with components having a high level of protein level sequence similarity with the components of those efflux pumps.Type: GrantFiled: October 1, 1998Date of Patent: December 17, 2002Assignee: Essential Therapeutics, Inc.Inventors: Suzanne Chamberland, May Lee, Olga Lomovskaya
-
Patent number: 6482921Abstract: The present invention relates to dihydro derivatives of the uridyl peptide antibiotics mureidomycin, pacidimycin and napsamycin which have antibiotic activity against a number of bacterial strains including strains resistant to current therapeutic antibiotics.Type: GrantFiled: June 11, 1999Date of Patent: November 19, 2002Assignee: Essential Therapeutics, Inc.Inventors: Constantine G. Boojamra, Rémy C. Lemoine, Scott Hecker, Ving J. Lee, Roger Léger